Efficacy of baricitinib in the treatment of rheumatoid arthritis.

about

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.The role of the JAK/STAT signal pathway in rheumatoid arthritis.

P2860

Q48109284-6326F68A-1318-4B3E-8548-0EB25565C000 Q55487787-DB400583-1FD1-4F8D-8C48-836233956524

P2860

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q38652849

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

@en

type

Item

label

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

@en

prefLabel

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

@en

P1476

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

@en

P2093

Bernard Bannwarth

http://www.w3.org/2001/XMLSchema#string

Christophe Richez

http://www.w3.org/2001/XMLSchema#string

Marie Kostine

http://www.w3.org/2001/XMLSchema#string

Marie-Elise Truchetet

http://www.w3.org/2001/XMLSchema#string

P2860

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis

Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis

Rheumatoid arthritis.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria.

P304

1399-1407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1359256

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Schaeverbeke

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28737053

http://www.w3.org/2001/XMLSchema#string

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

about

P2860

P2860

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698